How to buy PhaseBio Pharmaceuticals stock | $3.36

PhaseBio Pharmaceuticals, Inc is a biotechnology business based in the US. PhaseBio Pharmaceuticals shares (PHAS) are listed on the NASDAQ and all prices are listed in US Dollars. PhaseBio Pharmaceuticals employs 50 staff and has a trailing 12-month revenue of around USD$1.1 million.

How to buy shares in PhaseBio Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for PhaseBio Pharmaceuticals. Find the stock by name or ticker symbol: PHAS. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until PhaseBio Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$3.36, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of PhaseBio Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of PhaseBio Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

PhaseBio Pharmaceuticals share price

Use our graph to track the performance of PHAS stocks over time.

PhaseBio Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-12-29.

Latest market close	USD$3.36
52-week range	USD$2.6 - USD$6.7
50-day moving average	USD$3.8262
200-day moving average	USD$3.9159
Wall St. target price	USD$14.25
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.623

Buy PhaseBio Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy PhaseBio Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of PhaseBio Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

PhaseBio Pharmaceuticals price performance over time

Historical closes compared with the close of $3.36 from 2020-12-31

1 week (2021-01-07)	-17.04%
1 month (2020-12-15)	-24.32%
3 months (2020-10-15)	-1.18%
6 months (2020-07-15)	-31.01%

1 year (2020-01-15)	-36.36%
2 years (2019-01-15)	-8.45%
3 years (2018-01-13)	N/A
5 years (2016-01-13)	N/A

PhaseBio Pharmaceuticals financials

Revenue TTM	USD$1.1 million
Gross profit TTM	USD$-28,550,000
Return on assets TTM	-60.73%
Return on equity TTM	-211.62%
Profit margin	0%
Book value	$0.148
Market capitalisation	USD$95.7 million

TTM: trailing 12 months

Shorting PhaseBio Pharmaceuticals shares

There are currently 2.6 million PhaseBio Pharmaceuticals shares held short by investors – that's known as PhaseBio Pharmaceuticals's "short interest". This figure is 29% down from 3.7 million last month.

There are a few different ways that this level of interest in shorting PhaseBio Pharmaceuticals shares can be evaluated.

PhaseBio Pharmaceuticals's "short interest ratio" (SIR)

PhaseBio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of PhaseBio Pharmaceuticals shares currently shorted divided by the average quantity of PhaseBio Pharmaceuticals shares traded daily (recently around 185873.19660537). PhaseBio Pharmaceuticals's SIR currently stands at 14.14. In other words for every 100,000 PhaseBio Pharmaceuticals shares traded daily on the market, roughly 14140 shares are currently held short.

However PhaseBio Pharmaceuticals's short interest can also be evaluated against the total number of PhaseBio Pharmaceuticals shares, or, against the total number of tradable PhaseBio Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PhaseBio Pharmaceuticals's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 PhaseBio Pharmaceuticals shares in existence, roughly 120 shares are currently held short) or 0.2651% of the tradable shares (for every 100,000 tradable PhaseBio Pharmaceuticals shares, roughly 265 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against PhaseBio Pharmaceuticals.

Find out more about how you can short PhaseBio Pharmaceuticals stock.

PhaseBio Pharmaceuticals share dividends

We're not expecting PhaseBio Pharmaceuticals to pay a dividend over the next 12 months.

PhaseBio Pharmaceuticals share price volatility

Over the last 12 months, PhaseBio Pharmaceuticals's shares have ranged in value from as little as $2.6 up to $6.7. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PhaseBio Pharmaceuticals's is 1.9107. This would suggest that PhaseBio Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

PhaseBio Pharmaceuticals overview

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.

Frequently asked questions

• What percentage of PhaseBio Pharmaceuticals is owned by insiders or institutions?

  Currently 11.183% of PhaseBio Pharmaceuticals shares are held by insiders and 68.888% by institutions.

• How many people work for PhaseBio Pharmaceuticals?

  Latest data suggests 50 work at PhaseBio Pharmaceuticals.

• When does the fiscal year end for PhaseBio Pharmaceuticals?

  PhaseBio Pharmaceuticals's fiscal year ends in December.

• Where is PhaseBio Pharmaceuticals based?

  PhaseBio Pharmaceuticals's address is: 1 Great Valley Parkway, Malvern, PA, United States, 19355

• What is PhaseBio Pharmaceuticals's ISIN number?

  PhaseBio Pharmaceuticals's international securities identification number is: US7172241090

• What is PhaseBio Pharmaceuticals's CUSIP number?

  PhaseBio Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 717224109